Zhitong Finance App News, Heyu-B (02256.HK) announced that on December 16, 2025, Shanghai Heyu Biomedical Technology Co., Ltd. (“Heyu Pharmaceutical”) announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient administration in a phase II clinical trial for children with achondroplasia (“ACH”) aged 3-12.

Zhitong Finance App News, Heyu-B (02256.HK) announced that on December 16, 2025, Shanghai Heyu Biomedical Technology Co., Ltd. (“Heyu Pharmaceutical”) announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient administration in a phase II clinical trial for children with achondroplasia (“ACH”) aged 3-12.